Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain
Ignacio Salamanca de la Cueva, María González López, Reyes Roldán López, Beatriz Relinque Macías, Sergio Ocaña Jaramillo, Manuel Baca Cots, Javier Álvarez Aldeán, Benito Amil Pérez · 2026
Read Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain by Ignacio Salamanca de la Cueva, María González López, Reyes Roldán López, Beatriz Relinque Macías, Sergio Ocaña Jaramillo, Manuel Baca Cots, Javier Álvarez Aldeán, Benito Amil Pérez (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13313278.txt.
Description
Ignacio Salamanca de la Cueva leads a 2026 trial of a six-in-one infant vaccine in preterm babies in Spain. Babies born early face higher risk of death, disability, and infection, yet proof for these combined vaccines in very early births is thin.
The open-label phase IV trial tested a schedule of 2 plus 1 doses of the DTaP-IPV-HB-Hib vaccine, which guards against diphtheria, tetanus, whooping cough, hepatitis B, polio, and Hib disease. Babies were grouped by birth timing, from 24 to 27 weeks up to 34 to 36 weeks. In all, 143 infants got at least one dose, with 22 born at 24 to 27 weeks and 29 at 28 to 30 weeks per the counts in the report. The team described protection rates and both sought and unsought side effects, giving clinics rare data for the frailest babies.
Catalog record
| CREATOR | Ignacio Salamanca de la Cueva, María González López, Reyes Roldán López, Beatriz Relinque Macías, Sergio Ocaña Jaramillo, Manuel Baca Cots, Javier Álvarez Aldeán, Benito Amil Pérez |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41820 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |